^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Chronic Myelomonocytic Leukemia |
| Drug: | LENZ (lenzilumab) (GM-CSF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy of assigning treatment for participants with Chronic Myelomonocytic Leukaemia based on their individual molecular results (lenzilumab plus azacitidine versus sodium ascorbate plus azacitidine).
Excerpt:
...Detection of TET2 mutation or NRAS/KRAS/CBL mutation at a variant allele frequency...
Trial ID:
Source:
Title:
Efficacy of assigning treatment for participants with Chronic Myelomonocytic Leukaemia based on their individual molecular results (lenzilumab plus azacitidine versus sodium ascorbate plus azacitidine).
Excerpt:
...Detection of TET2 mutation or NRAS/KRAS/CBL mutation at a variant allele frequency ...
Trial ID:
Less C2 evidence
Source:
Title:
1847 Lenzilumab in Addition to Azacitidine Improves Complete Response Rates in Chronic Myelomonocytic LeukemiaClinically Relevant Abstract
Published date:
11/02/2023
Excerpt:
Subjects exhibiting RAS-pathway mutations (NRAS, KRAS, CBL) receive 24 cycles (every 28 days) of AZA (SC; 75 mg/m2 for 7 days) and LENZ...Interim analysis of the PREACH-M trial demonstrated that GM-CSF neutralization with LENZ/AZA, for the treatment of CMML with RAS-pathway mutations resulted in 55% CR, achieved early in treatment, durability up to 18 months, thus far, and no unexpected serious adverse events.
Secondary therapy:
azacitidine
